VassilikiPapadimitrakopoulouMD

Oncology • Houston, TX

Head & Neck Cancer

Professor of Medicine, University Tex Houston

Join to view full profile

Dr. Papadimitrakopoulou is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Papadimitrakopoulou's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161
Is this information wrong?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1992 - 1994
Icahn School of Medicine at Mount Sinai/Morningside/WestInternship, Internal Medicine, 1991 - 1992
University of Patras School of MedicineClass of 1990

Certifications & Licensure

TX State Medical License 1997 - 2025

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

BMS-214662 in Treating Patients With Solid Tumors Start of enrollment: 2000 Apr 01
Completed
Phase 1
Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 2
Erlotinib Prevention of Oral Cancer (EPOC) Start of enrollment: 2006 Nov 03
Completed
Phase 3
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2011 Jun 02
Completed
Phase 2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2014 Jul 31
Completed
Phase 2, Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Oct 01
Completed
Phase 2, Phase 3
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Start of enrollment: 2017 Nov 30
Completed
Phase 2
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2017 Mar 03
Completed
Phase 2
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer Start of enrollment: 2019 Feb 06
Recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

4 citations
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analy...
Jhanelle E Gray, Myung-Ju Ahn, Geoffrey R Oxnard, Frances A Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita M...> ;Clinical Cancer Research. 2023 Sep 1
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a P...
Edward B Garon, Alexander I Spira, Sarah B Goldberg, Jamie E Chaft, Vassiliki Papadimitrakopoulou, Tina Cascone, Scott J Antonia, Julie R Brahmer, D Ross Camidge, John...> ;Journal of Thoracic Oncology. 2023 Aug 1
1 citations
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-...
Marcelo V Negrao, Vassiliki A Papadimitrakopoulou, Andrew C Price, Alda L Tam, Muhammad Furqan, Sandeep T Laroia, Erminia Massarelli, Jose Pacheco, John V Heymach, Ann...> ;JTO Clinical and Research Reports. 2023 Mar 1
17 citations
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.
Juliann Chmielecki, Tony Mok, Yi-Long Wu, Ji-Youn Han, Myung-Ju Ahn, Suresh S Ramalingam, Thomas John, Isamu Okamoto, James Chih-Hsin Yang, Frances A Shepherd, Krishna...> ;Nature Communications. 2023 Feb 27
3 citations
Deep learning-based pathology image analysis predicts cancer progression risk in patients with oral leukoplakia.
Xinyi Zhang, Frederico O Gleber-Netto, Shidan Wang, Roberta Rayra Martins-Chaves, Ricardo Santiago Gomez, Nadarajah Vigneswaran, Arunangshu Sarkar, William N William J...> ;Cancer Medicine. 2023 Mar 1
2 citations
Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.
Joseph M Unger, Lu Qian, Mary W Redman, Susan S Tavernier, Lori Minasian, Ellen V Sigal, Vassiliki A Papadimitrakopoulou, Michael Leblanc, Charles S Cleeland, Samuel A...> ;Journal of the National Cancer Institute. 2023 Apr 11
4 citations
Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort.
William N William Jr, Jianjun Zhang, Xin Zhao, Edwin R Parra, Naohiro Uraoka, Heather Y Lin, S Andrew Peng, Adel K El-Naggar, Jaime Rodriguez-Canales, Jaejoon Song, An...> ;Cancer. 2023 Mar 1
62 citations
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MA...
Karen L Reckamp, Mary W Redman, Konstantin H Dragnev, Katherine Minichiello, Liza C Villaruz, Bryan Faller, Tareq Al Baghdadi, Susan Hines, Leah Everhart, Louise Highl...> ;Journal of Clinical Oncology. 2022 Jul 20
17 citations
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.
Alhalabi, O., Chen, J., Zhang, Y., Lu, Y., Wang, Q., Ramachandran, S., Tidwell, R., Han, G., Yan, X., Meng, J., Wang, R., Hoang, A., Wang, W., Song, J., Lopez, L., And...> ;Nature Communications. 2022 Apr 4
19 citations
Age Is Just a Number: Considerations for Older Adults in Cancer Clinical Trials.
Dany Habr, Lynn McRoy, Vassiliki A. Papadimitrakopoulou> ;Journal of the National Cancer Institute. 2021 Nov 2
15 citations
Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
Ray D. Page, Leylah Drusbosky, Hiba I. Dada, Victoria M. Raymond, Davey B. Daniel, Stephen G. Divers, Karen L. Reckamp, Miguel A. Villalona-Calero, Daniel Dix, Justin ...> ;Clinical Lung Cancer. 2021 Oct 10
49 citations
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Scott N. Gettinger, Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, Jeffrey D. Bradley, Thomas E. Stinchcombe, Natasha B. Lei...> ;JAMA Oncology. 2021 Sep 1
98 citations
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Journal for Immunotherapy of Cancer. 2021 Aug 1
23 citations
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP s...
Natasha B. Leighl, Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, James L. Wade, William J. Irvin, Sreekanth Reddy, Jeffrey Cra...> ;Journal for Immunotherapy of Cancer. 2021 Aug 1
2 citations
Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN).
Joshua A. Roth, Meghna S. Trivedi, Stacy W. Gray, Donald L. Patrick, Deborah M Delaney, Kate Watabayashi, Paul Litwin, Parth D. Shah, Katherine D. Crew, Monica Yee, Ma...> ;JCO Oncology Practice. 2021 Apr 2
6 citations
The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials.
Alda L. Tam, Vassiliki A. Papadimitrakopoulou, I. I. Wistuba, J. Jack Lee, Joe Ensor, Edward S. Kim, Neda Kalhor, George R. Blumenschein, Anne Tsao, John V. Heymach, R...> ;Clinical Radiology. 2021 Feb 1
14 citations
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.
Taofeek K. Owonikoko, Mary W. Redman, Lauren Averett Byers, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, Jeffrey D. Bradley, Thomas E. Stinchcombe, Natasha B....> ;Clinical Lung Cancer. 2021 Jan 10
37 citations
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
Vincent K. Lam, Jianjun Zhang, Carol C. Wu, Hai T. Tran, Lerong Li, Lixia Diao, Jing Wang, Waree Rinsurongkawong, Victoria M. Raymond, Richard B. Lanman, Jeff Lewis, E...> ;Journal of Thoracic Oncology. 2021 Apr 1
48 citations
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Mary W. Redman, Vassiliki A. Papadimitrakopoulou, Katherine Minichiello, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, Everett E. Vokes, Suresh S. Ramalingam, ...> ;The Lancet. Oncology. 2020 Dec 1
40 citations
Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC.
James W. Welsh, John V. Heymach, Chunxiao Guo, Hari Menon, Katherine Klein, Taylor R. Cushman, Vivek Verma, Kenneth R. Hess, Girish S. Shroff, Chad Tang, Ferdinandos S...> ;Journal of Thoracic Oncology. 2020 Dec 1
5 citations
SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)
Hossein Borghaei, Mary W. Redman, Karen Kelly, Saima N. Waqar, Francisco Robert, Gauri J. Kiefer, Philip J. Stella, Katherine Minichiello, David R. Gandara, Roy S. Her...> ;Clinical Lung Cancer. 2021 May 1
121 citations
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival an...
Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji Youn Han, Myung-Ju Ahn, Angelo Delmonte, Suresh S. Ramalingam, Sang We Kim, Frances A. Shepherd, Janessa Laskin, Yong He...> ;Annals of Oncology. 2020 Nov 1
35 citations
A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753).
Saiama N. Waqar, Mary W. Redman, Susanne M. Arnold, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, David R. Gandara, Thomas E. Stinchcombe, Natasha B. Leighl, S...> ;Clinical Lung Cancer. 2021 May 1
41 citations
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Aparna Hegde, Alexander Y. Andreev-Drakhlin, Jason Roszik, Le Huang, Shuang Liu, Kenneth R. Hess, Maria E. Cabanillas, Mimi I. Hu, Naifa L. Busaidy, Steven I. Sherman,...> ;ESMO Open. 2020 Jan 1
83 citations
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.
Lingzhi Hong, Marcelo V. Negrao, Seyedeh Dibaj, Runzhe Chen, Alexandre Reuben, Jadi M. Bohac, Xiaoke Liu, Ferdinandos Skoulidis, Tina Cascone, Kyle G. Mitchell, Hai T....> ;Journal of Thoracic Oncology. 2020 Sep 1
Join now to see all

Journal Articles

Landscape of EGFR -Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Post-Progression in EGFR-Mutant NSCLC
Stephen G Swisher, Vassiliki A Papadimitrakopoulou, John V Heymach, Jack A Roth, Jianjun Zhang, William N William, Bonnie S Glisson, Clinical Cancer Research
JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer
John D Minna, Jonathan M Kurie, J Jack Lee, Vassiliki A Papadimitrakopoulou, Neda Kalhor, Roy S Herbst, Clinical Cancer Research
Validation of the 12-Gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer
Cesar Moran, Jack A Roth, Yang Xie, John D Minna, Vassiliki A Papadimitrakopoulou, John V Heymach, Stephen G Swisher, Clinical Cancer Research

Lectures

Future of Novel Agents for Squamous Cell Carcinoma: Lung-MAP Trial
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protoc...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

Chutes & Ladders—Bayer Trims 2 Execs in Corporate ReshufflingSeptember 13th, 2019
#News #Biotech Pfizer Hires Ex-FDA, MD Anderson Researcher as Clinical Oncology LeadSeptember 11th, 2019
Pfizer Hires Ex-FDA, MD Anderson Researcher as Clinical Oncology LeadSeptember 11th, 2019
Join now to see all